MPM Capital Shows Commitment and Full Support to Biovitrum Transactions

The information in this press release is not for release, publication
or distribution, directly or indirectly, in or into the United
States, Australia, Canada, Hong Kong, Japan, South Africa,
Switzerland or Singapore.

Stockholm, Sweden - Dec 7, 2009 - As the second biggest shareholder
in Biovitrum AB (publ) (STO: BVT), MPM Capital ("MPM") publically
expresses its full support of the combination with Swedish Orphan.
The transaction has a very solid industrial logic and MPM want to
contribute to the creation of a new niche specialty pharmaceutical
company focused on rare diseases.

With its structure as manager of closed end private equity funds, it
was not possible for MPM Capital to put in new capital into the
upcoming rights issue, financing the Swedish Orphan transaction. MPM
has therefore sold shares in Biovitrum over the last month, with the
sole purpose of financing its participation in the upcoming rights
issue. The proceeds from the sale will go into exercising rights. MPM
now owns approximately 12.5% of the capital and votes in Biovitrum
and this is a position that MPM will defend by subscribing in the
rights issue.


About Biovitrum
Biovitrum is an international pharmaceutical company that markets
specialist pharmaceuticals in several regions. Using its expertise
and experience Biovitrum takes scientific innovation to patients with
significant unmet medical need. Research expertise and capabilities
are focused on development and production of biotechnology
therapeutics within our prioritized areas of hemophilia,
inflammation/autoimmune diseases, cancer supportive care and
malabsorption. Biovitrum has revenues of approximately SEK 1.2
billion and approximately 400 employees (prior to the Transaction).
Biovitrum's head office is located in Sweden and the share is listed
on the NASDAQ OMX Stockholm. For more information please visit
www.biovitrum.com.



For more information please contact:

Biovitrum AB (publ)
Erik Kinnman, Vice President Investor Relations
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com


Martin Nicklasson, CEO
Phone. +46 8 697 23 27



IMPORTANT NOTICE:
The information in this press release is not for release, publication
or distribution, directly or indirectly, in or into the United
States, Australia, Canada, Hong Kong, Japan, South Africa,
Switzerland or Singapore.
The information in this press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of the securities referred to herein in any jurisdiction in
which such offer, solicitation or sale would require preparation of
further prospectuses or other offer documentation, or be unlawful
prior to registration, exemption from registration or qualification
under the securities laws of any such jurisdiction.

The information in this press release does not constitute or form a
part of any offer or solicitation to purchase or subscribe for
securities in the United States. The securities mentioned herein have
not been, and will not be, registered under the United States
Securities Act of 1933 (the "Securities Act"). The securities
mentioned herein may not be offered or sold in the United States
absent registration or an exemption from the registration
requirements of the Securities Act. There will be no public offer of
securities in the United States.

The information in this press release may not be forwarded or
distributed to any other person and may not be reproduced in any
manner whatsoever. Any forwarding, distribution, reproduction, or
disclosure of this information in whole or in part is unauthorized.
Failure to comply with this directive may result in a violation of
the Securities Act or the applicable laws of other jurisdictions.

Biovitrum AB (publ) may be required to disclose the information
provided herein pursuant to the Swedish Securities Markets Act. The
information was provided for public release on December 7, 2009 at
3:30 p.m. CET.